Chimeric antigen receptor T cell (CART) therapy has developed as a powerful therapy in hematological malignancies. CD19 directed CART cells have resulted in complete response rates (RR) of ∼90% in acute lymphoblastic leukemia. However, the overall RR in other malignancies such as chronic lymphocytic leukemia is around 50%. This could be related to CART exhaustion induced by leukemia cells. Here, we aim to evaluate the role of inhibitory receptors/pathways in inducing CART cell dysfunction